Eli Lilly’s Alzheimer’s disease (AD) drug Kisunla ( donanemab) has demonstrated a growing benefit over three years in ...

Rates of diagnosis and treatment are low, so there is a need for diagnostic tests and biomarkers for classification and ...

Kisunla reduced cognitive decline by -0.6 at 18 months and then -1.2 at 36 months on the Clinical Dementia Rating Sum of Boxes (CDR-SB) in patients initially treated with Kisunla in the core study ...

The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous ...

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and ...

Kisunla (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

In delaying the progression of Alzheimer’s, Kisunla provides patients and their families with an “invaluable gift of time” according to its advocates. Anne White, the Executive Vice President spoke ...

The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.

This drug has the power to treat Alzheimer’s disease, strengthening memory and thinking skills. It’s called Kisunla, but the people WINK News reporter Maddie Herron spoke to in Naples at the ...